Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Ornithine alpha-ketoglutarate (OKG) is a compound formed from the amino acid ornithine and alpha-ketoglutarate, a key intermediate in the Krebs cycle. Its use in the context of “debility”—a general state of physical weakness or frailty, often associated with chronic illness or aging—has some basis in scientific investigation, though the evidence is not robust or conclusive.

Several clinical studies have explored the anabolic and anti-catabolic properties of OKG, particularly in populations suffering from muscle wasting or recovery issues, such as the elderly, post-surgical patients, or those with chronic illnesses. Research suggests that OKG supplementation may help promote protein synthesis, reduce muscle breakdown, and support nitrogen balance. Some trials have shown modest improvements in healing and muscle mass preservation, especially in malnourished or catabolic states. For example, a few small studies found that OKG supplementation improved nitrogen retention and reduced infection rates in surgical or trauma patients, which could be extrapolated to benefits in general debility.

However, systematic reviews and meta-analyses highlight that while results are promising, they are not uniformly positive, and many studies are limited by small sample sizes, heterogeneous populations, or methodological weaknesses. There is limited direct evidence for OKG specifically treating non-specific debility outside of specific catabolic or clinical contexts. Thus, while scientific rationale and some supportive studies exist, the overall strength of evidence is moderate at best (rated 2 out of 5), and OKG should not be considered a first-line or stand-alone therapy for debility.

More about ornithine alpha-ketoglutarate
More about Debility

Other ingredients used for Debility

Other health conditions supported by ornithine alpha-ketoglutarate

Products containing ornithine alpha-ketoglutarate

Pure Encapsulations Growth Hormone Support
Vitabase HGH Complex